Financial Performance - The company's revenue for Q3 2022 was CNY 214,100,881.83, representing a 16.79% increase year-over-year[5] - The net profit attributable to shareholders was CNY -19,539,556.10, a decrease of 61.75% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was CNY -0.0239, down 61.49% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 597,413,453.96, an increase of 12.3% compared to CNY 532,011,776.18 in the same period last year[22] - The net loss for the period was CNY 141,289,756.46, compared to a loss of CNY 101,970,958.00 in the previous year[21] - The net profit for the third quarter of 2022 was -88,301,832.21 CNY, compared to -76,486,558.47 CNY in the same period last year, representing an increase in net loss of approximately 15.5%[24] - The total comprehensive income for the third quarter was -84,160,488.27 CNY, compared to -76,612,587.69 CNY in the previous year, indicating a decline of about 9.5%[25] - The basic and diluted earnings per share were both -0.0481 CNY, compared to -0.0345 CNY in the same quarter last year, reflecting a worsening in earnings per share[25] - The company reported operating income of -79,895,791.55 CNY, compared to -68,933,560.22 CNY in the previous year, indicating a decline in operational performance[24] Assets and Liabilities - Total assets as of September 30, 2022, amounted to CNY 3,786,708,493.43, reflecting a 2.62% increase from the end of the previous year[5] - The company's total assets reached CNY 3,786,708,493.43, up from CNY 3,690,026,740.04, marking an increase of 2.6%[21] - The company's inventory increased to CNY 870,267,070.51, compared to CNY 820,953,599.87 in the previous quarter, indicating a rise of 6.0%[20] - Current assets totaled CNY 1,139,764,246.69, a slight increase from CNY 1,079,561,139.20, representing a growth of 5.6%[20] - Non-current assets amounted to CNY 2,646,944,246.74, compared to CNY 2,610,465,600.84, showing an increase of 1.4%[20] - The total liabilities decreased to CNY 1,412,705,737.13 from CNY 2,757,281,706.76, indicating a significant reduction of 48.9%[21] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY -28,327,997.49, a significant decline of 762.56%[5] - Cash flow from operating activities showed a net outflow of -28,327,997.49 CNY, compared to -3,284,164.08 CNY in the previous year, indicating a significant increase in cash outflow[26] - Cash flow from investing activities resulted in a net outflow of -70,479,138.29 CNY, compared to -309,901,057.83 CNY in the same period last year, showing an improvement in cash flow management[26] - Cash flow from financing activities generated a net inflow of 161,112,292.32 CNY, compared to 316,646,291.12 CNY in the previous year, indicating a decrease in financing activities[26] - The total cash and cash equivalents at the end of the period were 96,772,123.51 CNY, up from 46,488,862.00 CNY in the same period last year, reflecting a significant increase in liquidity[27] Operating Costs and Income - The company's operating costs rose by 32.51% to CNY 402,266,913.38, mainly due to increased plasma costs for blood products[10] - Total operating costs for Q3 2022 were CNY 679,084,214.56, up from CNY 614,587,565.43, reflecting a year-over-year increase of 10.5%[22] - Cash paid for purchasing goods and services rose by 32.46% year-on-year to ¥328,767,778.93, attributed to higher raw material procurement costs[11] Borrowings and Equity - The company's long-term borrowings increased by 281.62% to CNY 318,948,848.69, primarily due to project loans obtained by a subsidiary[9] - The capital reserve increased by 189.24% to CNY 754,221,087.47, attributed to the completion of a capital increase by a subsidiary[9] - The company's total equity attributable to shareholders increased by 47.02% to CNY 1,433,035,511.19 compared to the end of the previous year[5] - The company reported a significant increase in short-term borrowings, which rose to CNY 445,085,342.79 from CNY 434,893,006.77, an increase of 2.7%[21] Other Income and Expenses - Other income decreased by 67.68% to CNY 3,323,801.90, primarily due to a reduction in government subsidies received[10] - Research and development expenses for Q3 2022 were CNY 46,029,182.64, slightly down from CNY 49,792,899.26, reflecting a decrease of 5.5%[22] - The company recorded asset impairment losses of -92,551.36 CNY, which remained unchanged from the previous year[24] New Products and Partnerships - The company launched multiple new products, including various IgE antibody testing kits, which received medical device registration certificates[15] - The company signed guarantee contracts with Bank of Communications for a maximum amount of ¥41.6 million, indicating ongoing financial partnerships[16] Cash Inflows - Cash received from other operating activities increased by 42.67% year-on-year to ¥32,113,751.91, primarily due to an increase in deposits received[11] - Cash received from investment activities was ¥49,903,088.15, a significant increase of 168.02% year-on-year, reflecting the inclusion of tax refunds in investment cash flows[11] - The company raised ¥378,421,949.70 from minority shareholders during the reporting period, a new source of cash inflow[11] - Cash received from bank borrowings increased by 34.68% year-on-year to ¥672,043,149.41, indicating a rise in financing activities[11]

北京博晖创新生物技术集团股份有限公司 2022 年半年度报告全文 北京博晖创新生物技术集团股份有限公司 2022 年半年度报告 定 2022-03 2022 年 8 月 1 北京博晖创新生物技术集团股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人员 外的其他董事、监事、高级管理人员均保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 董事、监事、高级管理人员异议声明 | 姓名 | | 职务 | | 内容和原因 | | --- | --- | --- | --- | --- | | 无 | 无 | | 无 | | 无 公司负责人沈治卫、主管会计工作负责人董海锋及会计机构负责人(会计 主管人员)陈思绪声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构 成公司对投资者的实质承诺，请投资者注意投资风险。公司不存在因经营状 况、财务状况和持续盈利能力方面有严重不利影响 ...

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 175,394,242.89, representing a 10.23% increase compared to CNY 159,118,438.30 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 13,243,101.60, which is a 26.47% increase in loss compared to a loss of CNY 10,471,465.66 in the previous year[4] - The net profit for the current period is a loss of $26,680,596.65, compared to a loss of $21,160,208.78 in the previous period, reflecting a deterioration of approximately 26%[26] - The total comprehensive loss for the current period is $26,934,387.20, compared to a loss of $20,954,032.52 in the previous period, indicating an increase in losses of about 28.5%[26] Cash Flow and Operating Activities - The net cash flow from operating activities was a negative CNY 29,404,292.88, a decline of 138.79% from a negative CNY 12,313,915.41 in the same period last year[4] - The cash flow from operating activities shows a net outflow of $29,404,292.88, worsening from a net outflow of $12,313,915.41 in the previous period[28] - The company reported a cash inflow from financing activities of $132,357,092.92, compared to $127,719,272.37 in the previous period, showing a slight increase of about 3.5%[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,768,492,715.30, an increase of 2.13% from CNY 3,690,026,740.04 at the end of the previous year[5] - The total assets of Beijing Bohui Innovation Biotechnology Group Co., Ltd. as of March 31, 2022, amounted to CNY 3,768,492,715.30, an increase from CNY 3,690,026,740.04 at the beginning of the year[22] - Total liabilities rose to CNY 2,862,682,069.22 from CNY 2,757,281,706.76, an increase of about 3.8%[22] - The company's total equity decreased to CNY 905,810,646.08 from CNY 932,745,033.28, a decline of approximately 2.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,030, with the largest shareholder holding 39.03% of the shares[13] Financial Ratios and Performance Metrics - The weighted average return on net assets was -1.37%, a decrease of 40.88% compared to -0.81% in the previous year[5] - Basic and diluted earnings per share for the current period are both -$0.0162, compared to -$0.0128 in the previous period, reflecting a decline in earnings[26] Expenses - The company reported a 68.18% increase in financial expenses, amounting to an increase of CNY 5,093,400, primarily due to increased interest-bearing liabilities to support project construction[9] - Total operating costs for the current period are $200,887,913.43, up from $177,047,246.72 in the previous period, indicating an increase of about 13.4%[25] - Research and development expenses for the current period are $13,783,836.86, down from $15,815,565.02 in the previous period, indicating a decrease of approximately 12.9%[25] Cash and Equivalents - The company's cash and cash equivalents increased to CNY 103,472,840.41 from CNY 39,394,993.04, representing a growth of approximately 163.5%[19] - Cash and cash equivalents at the end of the period amount to $99,811,835.38, an increase from $73,949,719.56 at the end of the previous period, representing a growth of about 35%[29] Inventory and Receivables - Accounts receivable decreased to CNY 88,325,335.14 from CNY 92,107,187.76, a decline of about 4.2%[19] - Inventory increased slightly to CNY 832,530,828.17 from CNY 820,953,599.87, reflecting a growth of approximately 1.7%[19] Non-Current Assets - The company’s non-current assets totaled CNY 2,610,191,804.91, showing a slight decrease from CNY 2,610,465,600.84[22] Short-Term Borrowings - The company’s short-term borrowings increased to CNY 438,304,359.67 from CNY 434,893,006.77, a rise of approximately 0.9%[22] Audit Status - The company has not undergone an audit for the first quarter report[30]

Financial Performance - The company reported a significant loss during the reporting period, primarily due to the suspension and renovation of its subsidiary, Zhongke Biological, leading to a substantial decline in revenue[5]. - The loss was exacerbated by increased external debt and financial expenses to support the construction of the blood product production base in Qujing, Yunnan[5]. - The company's operating revenue for 2021 was ¥714,748,462.45, a decrease of 3.24% compared to ¥738,717,388.06 in 2020[23]. - The net profit attributable to shareholders was -¥322,176,629.03, representing a significant decline of 4,393.41% from a profit of ¥7,503,976.45 in 2020[23]. - The net cash flow from operating activities was ¥887,777.88, down 98.97% from ¥86,137,577.29 in the previous year[23]. - The total assets at the end of 2021 amounted to ¥3,690,026,740.04, a slight decrease of 0.68% from ¥3,715,242,196.65 at the end of 2020[23]. - The net assets attributable to shareholders decreased by 25.02% to ¥974,752,736.01 from ¥1,299,959,538.30 in 2020[23]. - The company reported a basic and diluted earnings per share of -¥0.3944, a decline of 4,386.96% from ¥0.0092 in 2020[23]. - The company’s revenue from core business after deductions was ¥682,179,143.93, down from ¥723,174,605.61 in 2020[23]. - The company’s quarterly revenue showed a decline in the fourth quarter, with a revenue of ¥182,736,686.27 compared to previous quarters[25]. Research and Development - The company has increased its R&D expenditure, indicating a commitment to innovation despite the financial challenges faced[5]. - R&D expenses surged by 69.13% to ¥81.48 million in 2021, reflecting the company's intensified investment in new product development[89]. - R&D investment amounted to ¥90.91 million in 2021, representing 12.72% of operating revenue, up from 10.31% in 2020[92]. - The number of R&D personnel increased by 26.47% to 129 in 2021, with a notable rise in the number of PhD holders from 7 to 15[91]. - The company is developing a fully automated real-time fluorescence nucleic acid detection system, which is expected to enhance market competitiveness upon product registration[90]. - The company aims to achieve product registration for various new products, which will enhance its competitive position in the industry and improve economic benefits[90]. Market and Industry Outlook - The company operates in the in-vitro diagnostics (IVD) sector, which is projected to grow from a market size of $67.11 billion in 2019 to $91.09 billion by 2027, with a CAGR of 4.8%[34]. - The Chinese in vitro diagnostic market is projected to reach ¥288.15 billion by 2030, becoming the largest consumer of in vitro diagnostic products globally[35]. - The blood products industry in China has 28 licensed manufacturers, with a total plasma collection of approximately 9,400 tons in 2021, reflecting a 13% increase from 2020[45]. - The demand for blood products in China exceeds 14,000 tons, indicating a significant supply-demand gap in the market[43]. - The company is focused on expanding its product line with various calibration solutions for blood and serum testing, set for registration renewal in January 2026[55]. Product Development and Sales - The company is set to launch a series of new diagnostic kits, including a combined test kit for rotavirus and enteric adenovirus, expected to be available by January 2024[54]. - A new atomic absorption spectrometer will be introduced in February 2023, designed for measuring lead and cadmium levels in human blood[54]. - The company plans to release multiple atomic absorption spectrometers by April 2024, which will measure various elements including copper, zinc, calcium, magnesium, and iron in human blood[54]. - The company’s blood products are primarily sourced from its plasma collection stations, which are regulated and licensed by provincial health authorities[61]. - The company’s biological products are subject to batch release management, ensuring quality control before market entry[61]. Operational Challenges and Risks - The management has indicated that the current losses are not sustainable and that there are no significant risks to the company's ongoing operations[5]. - Future plans and forward-looking statements in the report carry uncertainties and do not constitute a substantive commitment to investors[5]. - The company is actively addressing potential operational risks and has outlined corresponding measures in the management discussion section of the report[5]. - The company faces operational risks due to the recurring impacts of the COVID-19 pandemic on supply chains and sales[130]. Governance and Management - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and fulfill their duties according to regulations[146]. - The company has a total of 3 supervisors in the supervisory board, ensuring compliance and legality in the performance of duties by directors and senior management[147]. - The company maintains independence in personnel, assets, finance, institutions, and business from the controlling shareholder, ensuring autonomous operation[153]. - The company has established a good interactive relationship with investors, adhering to investor relations management regulations[151]. - The company has a structured decision-making process for determining the remuneration of directors and senior management, involving the nomination and compensation committee[177]. Future Outlook - The company has provided a positive outlook for 2022, projecting a revenue growth of 10% to 1.32 billion RMB[56]. - The company aims to enhance its international presence, with plans to enter two new overseas markets by the end of 2022[56]. - The company has set a future outlook with a revenue target of 1.5 billion yuan for the next fiscal year, indicating a projected growth rate of 25%[171]. - The company plans to enhance its digital marketing strategy, allocating an additional 30 million yuan to increase brand awareness and customer engagement[171].

Financial Performance - The company's operating revenue for Q3 2021 was ¥183,324,389.65, a decrease of 19.58% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥12,079,885.78, reflecting a decline of 155.81% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥12,419,578.55, a decrease of 161.51% compared to the previous year[3]. - The net profit for Q3 2021 was -76,486,558.47 CNY, compared to a net profit of 4,464,776.70 CNY in the same period last year, indicating a significant decline[33]. - The company reported a total comprehensive loss of -76,612,587.69 CNY for the quarter, compared to a comprehensive income of 3,114,472.97 CNY in the same quarter last year[33]. - The company incurred a total operating profit loss of -68,933,560.22 CNY, compared to an operating profit of 12,151,237.64 CNY in the previous year[33]. - The basic and diluted earnings per share were both -0.0345 CNY, compared to 0.0070 CNY in the same period last year[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,940,276,505.70, an increase of 6.06% from the end of the previous year[3]. - The total liabilities of the company as of September 30, 2021, were CNY 2,577,984,214.59, up from CNY 2,276,337,317.85, reflecting an increase of about 13.23%[30]. - The company's cash and cash equivalents stood at CNY 47,900,709.92 as of September 30, 2021, compared to CNY 44,595,499.31 at the end of 2020[28]. - The cash and cash equivalents at the end of the period were 46,488,862.00 CNY, down from 140,246,199.64 CNY at the end of the previous year[37]. - Accounts receivable decreased to CNY 115,159,768.63 from CNY 148,456,370.17, a decline of about 22.39%[28]. - Inventory increased to CNY 811,353,650.76 from CNY 789,549,320.61, showing a growth of approximately 2.43%[29]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥3,284,164.08, a decline of 104.74% year-to-date[3]. - The cash flow from operating activities showed a net outflow of -3,284,164.08 CNY, contrasting with a net inflow of 69,307,518.34 CNY in the previous year[36]. - The total cash inflow from financing activities was 1,273,781,564.69 CNY, while the cash outflow was 957,135,273.57 CNY, resulting in a net cash inflow of 316,646,291.12 CNY[37]. Expenses - Research and development expenses for the year-to-date reached ¥49,792,900, an increase of 51.16% compared to the same period last year[11]. - Management expenses for the year-to-date totaled ¥129,632,100, an increase of 76.70% year-on-year[11]. - The company's cash paid for purchasing goods and services was ¥248,198,900, an increase of 39.76% compared to the previous year[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,539[19]. - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares, with 12,000,000 shares pledged[19]. - The company’s management has 20,419,006 restricted shares, which are subject to a 25% release each year on the first trading day[22]. - There are no preferred shareholders or changes in restricted shares reported for the period[21]. Regulatory and Compliance - The company plans to enhance compliance training for its executives to prevent future regulatory violations following a recent incident involving stock sales by a senior executive[26]. - The board of directors is committed to strengthening adherence to relevant laws and regulations to avoid similar incidents in the future[26]. Other Information - The company reported a decrease in cash received from other operating activities by 42.55% year-to-date, totaling ¥22,508,400[14]. - Cash used for debt repayment from the beginning of the year to the end of the reporting period was CNY 537.98 million, a decrease of 33.36% compared to the same period last year, due to a reduction in bank loan repayments[17]. - Cash paid for other financing activities amounted to CNY 399.50 million, a decrease of 67.72% year-on-year, attributed to a reduction in related party transactions[17]. - The impact of exchange rate fluctuations on cash and cash equivalents was -CNY 159,600, an increase of 74.90% compared to the same period last year, mainly due to foreign currency translation[17]. - The company reported a decrease in other comprehensive income, with a total of -126,029.22 CNY for the quarter, compared to -1,350,303.73 CNY in the same period last year[33]. - The company did not report any net profit from subsidiaries prior to the merger during the period[34]. - The company has completed the extended audit work for a transaction and applied to resume the review of the application documents on August 4, 2021[24]. - The company terminated the issuance of shares to purchase assets and related fundraising on September 6, 2021[24].

北京博晖创新生物技术集团股份有限公司 2021 年半年度报告全文 北京博晖创新生物技术集团股份有限公司 2021 年半年度报告 定 2021-04 2021 年 08 月 1 北京博晖创新生物技术集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构 成公司对投资者的实质承诺，请投资者注意投资风险。公司不存在因经营状况、 财务状况和持续盈利能力方面有严重不利影响的风险因素。有关公司可能面对 的风险及公司应对措施等详见本报告第三节"管理层讨论与分析"中相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 错误！未定义书签。 | | --- ...

Financial Performance - The company's operating revenue for 2020 was ¥738,717,388.06, representing a 17.57% increase compared to ¥628,340,031.11 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥7,503,976.45, a significant increase of 195.11% from ¥2,542,755.03 in 2019[18]. - The net cash flow from operating activities improved to ¥86,137,577.29, a 339.09% increase from -¥36,027,044.31 in 2019[18]. - The total assets at the end of 2020 reached ¥3,715,242,196.65, marking a 37.88% increase from ¥2,694,604,343.18 at the end of 2019[18]. - The net assets attributable to shareholders increased by 26.04% to ¥1,299,959,538.30 from ¥1,031,395,597.18 in 2019[18]. - The basic earnings per share for 2020 was ¥0.0092, up 196.77% from ¥0.0031 in 2019[18]. - The weighted average return on net assets was 0.72% for 2020, an increase from 0.22% in 2019[18]. - The company reported a net profit excluding non-recurring gains and losses of ¥3,859,539.32, compared to a loss of -¥11,324,129.26 in 2019, reflecting a 134.08% improvement[18]. - The company achieved a total revenue of CNY 738.72 million in 2020, representing a year-on-year growth of 17.57%[67]. - Net profit attributable to shareholders reached CNY 7.50 million, a significant increase of 195.11% compared to the previous year[59]. Revenue and Sales - The company's operating revenue for 2020 was CNY 139.51 million, a decrease from CNY 227.96 million in 2019, representing a decline of approximately 38.8%[21]. - The net profit attributable to shareholders was a loss of CNY 13.45 million in 2020, compared to a profit of CNY 21.65 million in 2019, indicating a significant downturn[21]. - The in vitro diagnostic business saw a revenue decline of 8.77%, totaling CNY 282.09 million, with reagent sales down by 12.26%[67]. - The biopharmaceutical business reported a revenue of CNY 441.09 million, marking a 43.98% increase, driven by the consolidation of Zhongke Biology and increased vaccine sales[61]. - The company’s blood product sales model includes both distribution and direct sales, targeting hospitals and pharmaceutical distribution enterprises[34]. - The company’s human rabies vaccine is sold directly to disease prevention and control centers nationwide[34]. - The company reported a gross margin of 39.19% for its biopharmaceutical business, an increase of 10.08% year-on-year[70]. Market and Industry Insights - The global in vitro diagnostics (IVD) market was valued at $64 billion in 2019, with a year-on-year growth of 5%[38]. - The Chinese IVD market exceeded RMB 115 billion (over $17 billion) in 2019, growing approximately 15% year-on-year[39]. - The domestic market for molecular diagnostics is one of the fastest-growing segments, accounting for about 20% of the overall IVD market[40]. - The market share of domestic products in the immunology sector is approximately 25%-30%, while biochemical diagnostics exceed 50%[41]. - The blood products industry is experiencing consolidation, with the top five companies holding 80%-85% of the market share globally[45]. - The domestic IVD industry is characterized by a low concentration, with over 600 companies, and the top 20 companies holding only about 30% market share[42]. - The blood products industry in China has high barriers to entry and strict regulations, with significant oversight on plasma collection and product quality[46]. - The domestic market for blood products has substantial growth potential, with the average consumption of immunoglobulin and coagulation factor products in developed countries far exceeding that of China[47]. Research and Development - The company has developed over 20 patents related to its unique microfluidic nucleic acid chip technology, which is a key driver for its HPV testing products[29]. - The company is actively involved in the research and development of vaccines, including human rabies vaccines, expanding its product offerings in the biological products sector[33]. - The company has initiated the development of a new qPCR platform that enhances detection sensitivity and reduces testing time[82]. - The company has completed the prototype manufacturing of a new atomic fluorescence spectrometer, meeting all acceptance criteria[84]. - The company is expanding its product line with new nucleic acid testing kits, including those for COVID-19 and respiratory pathogens, expected to launch in the next two to three years[85]. - The company has invested approximately 36.18 million yuan in the research and development of blood products during the reporting period[86]. - The company aims to enhance the comprehensive utilization of plasma resources to improve product competitiveness[86]. - The R&D investment as a percentage of operating revenue for the past three years indicates a consistent commitment to innovation and product development[87]. - The company reported a significant increase in R&D spending compared to previous years, with a total of ¥76,140,363.67 in 2020[88]. Cash Flow and Financing - The net cash flow from operating activities increased by 339.09% to ¥86,137,577.29 compared to a net outflow of ¥36,027,044.31 in the previous year[94]. - Total cash inflow from operating activities was ¥788,361,005.62, reflecting a year-on-year increase of 13.37%[94]. - Cash inflow from financing activities rose by 192.75% to ¥2,953,185,035.69, primarily due to a prepayment of ¥1.122 billion from a development company[95]. - The net cash flow from financing activities also increased by 207.00% to ¥288,773,772.76[94]. - Investment activities saw a significant cash inflow increase of 37,043.93% to ¥769,510,828.12, attributed to cash recovered from short-term financial management[95]. - The company reported a net increase in cash and cash equivalents of ¥13,176,556.93, a turnaround from a decrease of ¥72,502,275.21 in the previous year, marking an increase of 118.17%[94]. Corporate Governance and Compliance - The company guarantees that all information provided during the transaction process is true, accurate, and complete, with no false records or misleading statements[144]. - The company has fulfilled its legal disclosure and reporting obligations, with no undisclosed contracts, agreements, arrangements, or other matters[145]. - The company has not been subject to any major administrative penalties or criminal sanctions in the last thirty-six months[146]. - The company has committed to providing true, accurate, and complete original written materials to all intermediary institutions involved in the transaction[145]. - The company has not participated in any major asset restructuring that is prohibited by regulations in the last thirty-six months[145]. - The company has undertaken to bear all legal responsibilities for any economic losses or claims arising from violations of the commitments made[146]. Future Outlook and Strategic Plans - The company provided a future outlook, projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion strategies[147]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[147]. - The company aims to enhance its core competitiveness through increased R&D investment in its testing and detection business[143]. - The company plans to continue increasing its market development efforts alongside R&D for new products[140]. - The company aims to implement a new customer engagement strategy, which is projected to improve customer retention rates by 30%[147]. Asset Management and Investments - The company has entrusted RMB 752.5 million in bank wealth management products, with no overdue amounts reported[189]. - The company plans to use up to RMB 580 million of idle funds for cash management through bank wealth management products[196]. - The company approved a total credit limit of up to RMB 580 million for comprehensive financing from banks and financial institutions[197]. - The company signed a comprehensive credit contract with Beijing Bank for a maximum credit limit of RMB 30 million[198]. Rental Income and Property Management - The company reported rental income of 2.047 million yuan from properties located in Beijing during the reporting period[178]. - The company generated rental income of 7.1275 million yuan from temporarily idle properties in Beijing during the reporting period[178]. - The total rental income from the properties contributed over 10% to the company's total profit for the reporting period[178]. - The company has a lease agreement with Zhongguancun Life Science Park Development Co., Ltd. for office space, generating a rental income of 3.1442 million yuan[178].

北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 北京博晖创新生物技术股份有限公司 2021 年第一季度报告 定 2021-03 2021 年 04 月 1 北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新生物技术股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 159,118,438.30 | 139,506,502.75 | 14.06% | | 归属于上市公司股东的净利润（元） | -10,471,465.66 | -13,453,68 ...

北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 北京博晖创新生物技术股份有限公司 1 北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人翟晓枫、主管会计工作负责人董海锋及会计机构负责人(会计主 管人员)李娟声明：保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新生物技术股份有限公司 2020 年第三季度报告全文 2020 年第三季度报告 定 2020-06 2020 年 10 月 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,668,429,687.48 | 2,694,604,343.18 | | 36.14% | | 归属 ...

```markdown [Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section provides an overview of the report's structure, including important disclaimers, the table of contents, and definitions of key terms [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The company's management guarantees the truthfulness and completeness of this semi-annual report, with no plans for profit distribution or capital reserve conversion during the period - The company's management guarantees the truthfulness, accuracy, and completeness of the report content and assumes legal responsibility[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section outlines the report's overall structure, covering twelve main parts from company overview to financial statements [Definitions](index=4&type=section&id=%E9%87%8A%E4%B9%89) This section defines specific terms, abbreviations, and professional jargon used in the report for investor clarity, including company entities and key products [Company Profile and Key Financial Indicators](index=5&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section introduces the company's profile and key financial indicators, including its basic information and performance metrics [Company Profile](index=5&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Beijing Bohui Innovation Biotechnology Co., Ltd. (stock code: 300318) is listed on the Shenzhen Stock Exchange, with Zhai Xiaofeng as its legal representative | Item | Information | | :--- | :--- | | Stock Abbreviation | Bohui Innovation | | Stock Code | 300318 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Zhai Xiaofeng | [Key Accounting Data and Financial Indicators](index=6&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, revenue decreased by 7.89% year-over-year, and net profit attributable to shareholders turned to a loss, declining by 1,147.09%, while operating cash flow significantly improved by 196.21% and total assets grew by 34.74% | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 270.78 | 293.96 | -7.89% | | Net Profit Attributable to Shareholders (Million Yuan) | -15.95 | 1.52 | -1,147.09% | | Net Cash Flow from Operating Activities (Million Yuan) | 49.87 | -51.83 | 196.21% | | Basic EPS (Yuan/Share) | -0.0195 | 0.0019 | -1,126.32% | | **Indicator** | **Period-End** | **Prior Year-End** | **YoY Change** | | Total Assets (Billion Yuan) | 3.63 | 2.69 | 34.74% | | Net Assets Attributable to Shareholders (Billion Yuan) | 1.27 | 1.03 | 23.58% | [Non-Recurring Gains and Losses](index=7&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled 0.95 million Yuan, primarily comprising government subsidies of 2.91 million Yuan and net non-operating and investment-related losses | Item | Amount (Million Yuan) | | :--- | :--- | | Government Subsidies | 2.91 | | Net Other Non-Operating Income and Expenses | -1.30 | | Fair Value Change Gains and Losses from Trading Financial Assets | -0.83 | | Gains and Losses from Disposal of Non-Current Assets | 0.36 | | **Total** | **0.95** | [Business Overview](index=8&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E5%85%AC%E5%8F%B8%E4%B8%9A%E5%8A%A1%E6%A6%82%E8%A6%81) This section details the company's core businesses, significant asset changes, and competitive advantages [Main Businesses During the Reporting Period](index=8&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main businesses include testing and diagnostics, focusing on in-vitro diagnostic products like trace element and HPV nucleic acid detection systems, and blood products, managed by subsidiaries Hebei Daan and Guangdong Weilun, offering human albumin and immunoglobulins [Testing and Diagnostics Business](index=8&type=section&id=1%E3%80%81%E6%A3%80%E9%AA%8C%E6%A3%80%E6%B5%8B%E4%B8%9A%E5%8A%A1) The core testing and diagnostics products are closed-system human trace element detection and microfluidic nucleic acid chip-based HPV detection, with stable market presence and rapid growth respectively, driven by instrument and reagent sales - The company's testing and diagnostics business primarily offers human trace element detection systems and HPV detection products, both closed-system solutions[25](index=25&type=chunk)[26](index=26&type=chunk) - The HPV product, leveraging the company's unique microfluidic nucleic acid chip technology, achieves fully automated nucleic acid molecular detection, making it the first fully automated nucleic acid molecular detection product in China[26](index=26&type=chunk) [Blood Products Business](index=9&type=section&id=2%E3%80%81%E8%A1%80%E6%B6%B2%E5%88%B6%E5%93%81%E4%B8%9A%E5%8A%A1) Blood products business, operated by Hebei Daan and Guangdong Weilun, includes albumin, immunoglobulins, and coagulation factors, relying on plasma stations for raw materials and strict batch release, with sales through distribution and direct channels - The blood products business is operated by subsidiaries Hebei Daan and Guangdong Weilun, with raw plasma supplied by their affiliated plasma collection stations[29](index=29&type=chunk)[30](index=30&type=chunk) | Category | Main Varieties | Application Area | | :--- | :--- | :--- | | Albumin | Human Albumin | Regulates plasma osmotic pressure, used in oncology, liver disease treatment | | Immunoglobulin | Human Immunoglobulin, Intravenous Human Immunoglobulin, etc | Treatment of immune diseases, passive immunization against infectious diseases | | Coagulation Factors | Human Prothrombin Complex | Used for treating coagulation factor deficiencies | [Significant Changes in Major Assets](index=12&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%BB%E8%A6%81%E8%B5%84%E4%BA%A7%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8C%96%E6%83%85%E5%86%B5) Major assets saw significant changes due to the merger of subsidiary Hebei Daan with Zhongke Bio, leading to substantial increases in fixed assets, intangible assets, construction in progress, and goodwill, while cash grew from Hebei Daan's capital injection | Major Asset | Period-End vs. Year-Start Change | Explanation of Significant Change | | :--- | :--- | :--- | | Fixed Assets | +51.96% | Primarily due to the merger with Zhongke Bio | | Intangible Assets | +66.18% | Primarily due to the merger with Zhongke Bio | | Construction in Progress | +46.03% | Primarily due to the merger with Zhongke Bio and the capitalization of the company's Phase II base | | Monetary Funds | +329.4% | Primarily due to capital injection received by Hebei Daan | | Goodwill | +41.16% | Primarily due to new goodwill from the merger with Zhongke Bio | [Analysis of Core Competencies](index=13&type=section&id=%E4%B8%89%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competencies include continuous technological innovation, high-barrier products, effective quality management, and talent development, with exclusive microfluidic chip technology in diagnostics and strengthening R&D in blood products, adhering to GMP standards - The company has undertaken multiple national-level major scientific research projects in testing and diagnostics, holding exclusive patented technology for its microfluidic chip molecular diagnostic platform[49](index=49&type=chunk)[50](index=50&type=chunk) - R&D in blood products advanced, with subsidiary Hebei Daan obtaining drug registration certificates for intravenous human immunoglobulin and human prothrombin complex in July 2020[49](index=49&type=chunk) - The company prioritizes quality system development, having obtained medical device GMP, ISO13485, and ISO9001 certifications, with blood product manufacturing facilities compliant with GMP standards[51](index=51&type=chunk)[52](index=52&type=chunk) [Management Discussion and Analysis](index=15&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section discusses the company's operational performance, financial status, and risk management strategies [Overview](index=15&type=section&id=%E4%B8%80%E3%80%81%E6%A6%82%E8%BF%B0) In H1 2020, revenue decreased by 7.89% to 271 million Yuan, and net profit attributable to parent company was -15.95 million Yuan, down 1147.09% due to COVID-19 impacting testing and diagnostics, while blood products grew by 16%, with Q2 losses narrowing - Testing and diagnostics business: Achieved main business revenue of **102 million Yuan**, a year-over-year decrease of **31.35%**, primarily due to reduced hospital health screening volumes during the pandemic[57](index=57&type=chunk) - Blood products business: Achieved main business revenue of **169 million Yuan**, a year-over-year increase of **15.98%**, primarily due to a significant sales increase of intravenous human immunoglobulin produced by Guangdong Weilun as an epidemic prevention drug[61](index=61&type=chunk) - R&D made positive progress, with Hebei Daan obtaining drug registration certificates for intravenous human immunoglobulin and human prothrombin complex in July 2020, enhancing its product structure[62](index=62&type=chunk) - Hebei Daan completed a capital increase and acquisition of **72% equity** in Zhongke Bio, strengthening capital and optimizing the competitive landscape[62](index=62&type=chunk) [Analysis of Main Business Operations](index=20&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Main business operations showed divergence due to the pandemic, with instrument, software, reagent, and albumin revenues declining by 20-35%, while intravenous immunoglobulin (IVIG) revenue nearly doubled, despite a decrease in its gross margin due to rising costs | Item | Current Period | Prior Year Period | YoY Change | Main Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 271 | 294 | -7.89% | COVID-19 impacted testing business revenue | | Financial Expenses (Million Yuan) | 17.38 | 11.72 | +48.22% | Increase in interest expenses on borrowings | | R&D Investment (Million Yuan) | 41.61 | 34.58 | +20.32% | - | | Net Cash Flow from Operating Activities (Million Yuan) | 49.87 | -51.83 | +196.21% | Strengthened collection management and expenditure control | | Product/Service | Operating Revenue (Million Yuan) | Gross Margin | Operating Revenue YoY Change | | :--- | :--- | :--- | :--- | | Instruments and Software | 32.99 | 30.96% | -30.99% | | Reagents | 55.26 | 78.44% | -34.18% | | Albumin | 80.49 | 24.88% | -23.25% | | IVIG | 63.90 | 40.94% | +99.89% | [Analysis of Non-Core Business Operations](index=21&type=section&id=%E4%B8%89%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Non-core operations negatively impacted profit, with investment losses of 0.91 million Yuan from wealth management and derivatives, and non-operating expenses of 1.45 million Yuan due to COVID-19 donations - Investment income was **-0.91 million Yuan**, mainly due to losses from wealth management products and matured forward foreign exchange and risk option contracts[73](index=73&type=chunk) - Non-operating expenses totaled **1.45 million Yuan**, primarily due to donations for the COVID-19 pandemic[74](index=74&type=chunk) [Analysis of Assets and Liabilities](index=22&type=section&id=%E5%9B%9B%E3%80%81%E8%B5%84%E4%BA%A7%E3%80%81%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) At period-end, the company's asset and liability structure significantly changed, with non-current assets like fixed assets and construction in progress increasing, cash substantially rising, inventory share decreasing, and short-term debt increasing while long-term debt decreased [Analysis of Investment Activities](index=23&type=section&id=%E4%BA%94%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Investment increased by 169.63% year-over-year, primarily for capital injection related to Hebei Daan equity compensation, and the company acquired 72% of Zhongke Bio for 41.76 million Yuan via non-monetary asset exchange, with the deal closed - Investment during the reporting period was **207 million Yuan**, a year-over-year increase of **169.63%**, mainly for capital injection related to Mr. Du Jiangtao's compensation to Hebei Daan on behalf of Yunnan Watson[79](index=79&type=chunk) - Acquired **72% equity** in Zhongke Bio-Pharmaceutical Co., Ltd. for **41.76 million Yuan** through non-monetary asset exchange, with equity transfer completed[81](index=81&type=chunk) [Analysis of Major Holding and Participating Companies](index=25&type=section&id=%E4%B8%83%E3%80%81%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) Key subsidiaries showed mixed performance, with blood product subsidiary Hebei Daan achieving a net profit of 16.31 million Yuan, while Guangdong Weilun incurred a loss of 8.26 million Yuan, and US-based testing and diagnostics subsidiary Advion, Inc. reported a loss of 14.12 million Yuan | Company Name | Main Business | Operating Revenue (Million Yuan) | Net Profit (Million Yuan) | | :--- | :--- | :--- | :--- | | Hebei Daan Pharmaceutical Co., Ltd. | Blood Products | 100.36 | 16.31 | | Guangdong Weilun Bio-Pharmaceutical Co., Ltd. | Blood Products | 115.16 | -8.26 | | Advion,Inc. | Testing and Diagnostics | 31.60 | -14.12 | [Risks Faced by the Company and Countermeasures](index=25&type=section&id=%E4%B9%9D%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces operational risks from the ongoing COVID-19 pandemic, particularly impacting testing and diagnostics, potential product safety risks in blood products, regulatory risks for plasma stations, and R&D failure risks for medical devices, addressed by strengthening management, quality systems, plasma station digitalization, and advanced R&D tools - COVID-19 impact: Testing and diagnostics revenue decreased, and plasma collection was affected. Countermeasures include strengthening scientific management and cost-saving initiatives[89](index=89&type=chunk)[90](index=90&type=chunk) - Product safety risk: Blood products use special raw materials, posing potential risks of unknown virus transmission. Countermeasures include improving the quality management system and strictly adhering to GMP standards[91](index=91&type=chunk)[92](index=92&type=chunk) - Regulatory risk: Plasma collection station operations require continuous standardization, with risks of penalties due to management oversight. Countermeasures include increasing IT investment for full traceability[93](index=93&type=chunk) - R&D risk: Medical device R&D has long cycles and high difficulty, potentially facing failure risks. Countermeasures include strengthening project management to improve success rates[94](index=94&type=chunk)[95](index=95&type=chunk) [Significant Matters](index=27&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section highlights significant events, including major related-party transactions and subsidiary developments [Major Related-Party Transactions](index=29&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) Several major related-party transactions occurred, including 7.69 million Yuan in product sales to Inner Mongolia Junzheng Group for donations, a planned share issuance to Zhuhai Aosen (controlled by the actual controller) for asset acquisition, and a capital increase for Hebei Daan involving related parties, where the company waived its pre-emptive rights - Subsidiaries Guangdong Weilun and Hebei Daan signed drug purchase and sales contracts totaling **7.69 million Yuan** with related party Inner Mongolia Junzheng Group for public welfare donations to combat the epidemic[113](index=113&type=chunk) - The company plans to issue shares to Zhuhai Aosen, controlled by actual controller Mr. Du Jiangtao, to acquire assets and raise supporting funds[114](index=114&type=chunk) - The company introduced external investors (including related party Shengtai Technology) for a capital increase in subsidiary Hebei Daan and waived its pre-emptive rights[115](index=115&type=chunk) [Significant Matters of Subsidiaries](index=34&type=section&id=%E5%8D%81%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) Subsidiaries saw several significant developments, including Hebei Daan's acquisition of 72% of Zhongke Bio (human rabies vaccine producer), a provincial high-tech industrialization project for Hebei Daan, and the expiration of a plasma station license for Guangdong Weilun in February 2020 - Subsidiary Hebei Daan completed the acquisition of **72% equity** in Zhongke Bio, which primarily produces human rabies vaccine[132](index=132&type=chunk) [Share Changes and Shareholder Information](index=35&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section outlines changes in share capital and shareholder structure, including major shareholders' holdings [Share Capital Changes](index=35&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the total share capital remained at 816,900,495 shares, but the share structure changed as 12,677,034 restricted shares converted to unrestricted shares due to automatic unlocking for senior executives, reducing the restricted share percentage from 11.31% to 9.75% - Total share capital remained unchanged at **816,900,495 shares**[137](index=137&type=chunk) - Restricted shares decreased by **12,677,034 shares**, with a corresponding increase in unrestricted shares, due to automatic unlocking for senior executives[137](index=137&type=chunk) [Shareholder Numbers and Shareholding Structure](index=36&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had 27,670 common shareholders, with the actual controller Du Jiangtao and his spouse Hao Hong collectively holding over 51% of shares, and the top ten shareholders primarily being natural persons with a stable structure | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Du Jiangtao | 39.03% | 318,811,388 | | Hao Hong | 12.59% | 102,809,951 | | Yang Qi | 7.48% | 61,123,211 | | Mei Yingjun | 3.55% | 29,034,177 | | Du Jianghong | 3.00% | 24,478,560 | - Among the top ten shareholders, Du Jiangtao and Hao Hong are spouses, and Du Jiangtao and Du Jianghong are siblings[143](index=143&type=chunk) [Directors, Supervisors, and Senior Management](index=41&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E6%83%85%E5%86%B5) This section details changes in the board of directors, supervisors, and senior management personnel [Changes in Directors, Supervisors, and Senior Management](index=42&type=section&id=%E4%BA%8C%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the board, supervisory board, and senior management underwent significant changes due to elections, resignations, and term expirations, with new vice chairmen, directors, general managers, independent directors, supervisors, and deputy general managers appointed - Appointments: Mr. Jiang Yan was appointed General Manager, Mr. Wang Wei and Mr. Zhang Lei as Deputy General Managers, and Mr. Dong Haifeng as Chief Financial Officer[157](index=157&type=chunk) - Board and management changes: Former Chairman Lu Xinqun, Director Yang Qi, and other executives departed due to term expiration. New members elected include Shen Zhiwei as Vice Chairman, Jiang Yan and Wang Wei as Directors, and Ban Jun and Zhang Xiaosu as Independent Directors[157](index=157&type=chunk) [Financial Report](index=44&type=section&id=%E7%AC%AC%E5%8D%81%E4%B8%80%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's financial statements, including balance sheets, income statements, and cash flow statements [Financial Statements](index=44&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity, reflecting H1 2020 financial position, operating results, and cash flows [Consolidated Balance Sheet](index=44&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2020, total assets were 3.63 billion Yuan, up 34.74% from year-start, and total liabilities were 2.22 billion Yuan, up 34.95%, primarily due to the acquisition of Zhongke Bio and subsidiary capital injections, with equity attributable to parent company increasing by 23.58% to 1.27 billion Yuan | Item | June 30, 2020 (Billion Yuan) | December 31, 2019 (Billion Yuan) | | :--- | :--- | :--- | | Total Assets | 3.63 | 2.69 | | Total Liabilities | 2.22 | 1.64 | | Total Equity Attributable to Parent Company Owners | 1.27 | 1.03 | [Consolidated Income Statement](index=50&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In H1 2020, total operating revenue was 271 million Yuan, down 7.89%, with operating profit turning to a loss of -11.69 million Yuan, and net profit attributable to parent company significantly declining to -15.95 million Yuan from 1.52 million Yuan last year | Item | H1 2020 (Million Yuan) | H1 2019 (Million Yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 270.78 | 293.96 | | Operating Profit | -11.69 | 8.67 | | Net Profit Attributable to Parent Company Owners | -15.95 | 1.52 | [Consolidated Cash Flow Statement](index=53&type=section&id=5%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Operating cash flow significantly improved to 49.87 million Yuan from -51.83 million Yuan last year, while investing activities had a net outflow of 196 million Yuan for equity capital injections, and financing activities had a net inflow of 245 million Yuan from borrowings and capital contributions, increasing cash and cash equivalents to 129 million Yuan | Item | H1 2020 (Million Yuan) | H1 2019 (Million Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 49.87 | -51.83 | | Net Cash Flow from Investing Activities | -196.06 | -76.75 | | Net Cash Flow from Financing Activities | 245.39 | 63.98 | | Net Increase in Cash and Cash Equivalents | 98.93 | -64.67 | [Changes in Consolidation Scope](index=146&type=section&id=%E5%85%AB%E3%80%81%E5%90%88%E5%B9%B6%E8%8C%83%E5%9B%B4%E7%9A%84%E5%8F%98%E6%9B%B4) The consolidation scope changed due to a non-same-control business combination, with subsidiary Hebei Daan acquiring 72% of Zhongke Bio for 41.76 million Yuan via non-monetary asset exchange, consolidating it as of June 30, 2020, and generating 324 million Yuan in goodwill - Zhongke Bio-Pharmaceutical Co., Ltd. was included in the consolidation scope due to a non-same-control business combination[633](index=633&type=chunk) | Merger Cost Item | Amount (Million Yuan) | | :--- | :--- | | Fair Value of Non-Cash Assets | 41.76 | | Less: Fair Value Share of Identifiable Net Assets Acquired | -282.03 | | **Goodwill** | **323.79** | [Other Significant Matters](index=158&type=section&id=%E5%8D%81%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company segmented its operations into testing and diagnostics and blood products; in H1 2020, the testing segment generated 102 million Yuan in revenue with an operating loss of -29.93 million Yuan, while the blood products segment generated 169 million Yuan in revenue with an operating profit of 18.24 million Yuan, showing divergent performance | Item | Testing & Diagnostics Segment (Million Yuan) | Blood Products Segment (Million Yuan) | | :--- | :--- | :--- | | Operating Revenue | 101.82 | 168.93 | | Operating Profit | -29.93 | 18.24 | | Net Profit | -29.12 | 12.83 | | Total Assets (Billion Yuan) | 2.28 | 2.19 | | Total Liabilities (Billion Yuan) | 0.77 | 1.49 | [Catalogue of Reference Documents](index=166&type=section&id=%E7%AC%AC%E5%8D%81%E4%BA%8C%E8%8A%82%20%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists reference documents available for inspection, including signed report texts by legal representatives and financial officers, original copies of all publicly disclosed documents, and announcements from the reporting period [Reference Documents](index=166&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6) This section lists reference documents available for inspection, including signed report texts by legal representatives and financial officers, original copies of all publicly disclosed documents, and announcements from the reporting period ```